A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.
Diagnosed with alopecia areata;
Starting/using a systemic treatment for alopecia areata;
Informed consent for registry participation obtained from patient and/or caretaker.
Not sufficiently capable of understanding the Dutch language;
Not willing to participate.
All adult patients with alopecia areata starting/using systemic treatment, who are willing to provide voluntary informed consent prior to inclusion in the registry and comply with the requirements of the registry. All patients will be recruited in the dermatology outpatient clinics.
Cohort
Prospective
Not listed
Effectiveness of systemic treatments
The primary study parameters and endpoints include assessing the short- and long-term effectiveness of various systemic treatments for alopecia areata. Effectiveness ranging from strong improvement to strong deterioration (5 categories).
Safety of systemic treatments
The primary study parameters and endpoints include assessing the short- and long-term safety of various systemic treatments for alopecia areata. Measured by the number of participants with treatment-related adverse events.
Epidemiological data
Demographics, ethiopathogenesis, co-morbidities, family history, clinical features, treatment history.
Physician Reported - Severity of Alopecia Tool (SALT Score)
The SALT score measures hair loss on a scale of 0 (no scalp hair loss) to 100 (complete scalp hair loss).
Dermatology Life Quality Index (DLQI, 10 items)
The DLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week, scored 0-30.
Alopecia Areata Symptom Impact Scale (AASIS, 13 items)
The AASIS consists of 13 questions concerning disease-specific patient-reported outcomes measure about symptoms related to alopecia areata and how these symptoms interfere with daily functioning.
Click on the lead sponsor to view all of their trials.
